Glycine

—

evidence score

amino acid

aminoacetic acidglycocoll

Glycine is the simplest amino acid and the most abundant in the human body by molar weight. It is a major inhibitory neurotransmitter in the spinal cord and brainstem, a key component of collagen (33% of collagen residues), a precursor to glutathione, and a co-agonist at NMDA receptors. Multiple RCTs confirm 3g before bed improves sleep quality, reduces time to sleep onset, and decreases daytime sleepiness. It is also central to the "methyl sink" theory of aging and has significant longevity implications in the glycine-NAC (GlyNAC) combination.

Evidence

No score yet

Safety

Unknown safety profile

Clinical Status

No formal phase listed

Research Sync

Not synced yet

Dosing

Typical

3000 mg

1000 mgRange10000 mg

Frequencydaily

Set height & weight in Settings to see your dose.

Pharmacology

Half-life~0.5-1 hour (plasma)

OnsetSleep effects acute (30-60 min pre-bed); metabolic effects weeks

DurationShort plasma half-life; tissue incorporation ongoing

Routes

oral

Evidence Score

—

0 studies indexed

Scoring Factors

Volume(40%)—

Quality(30%)—

Sample Size(10%)—

Consistency(10%)—

Replication(5%)—

Recency(5%)—

Evidence Levels

AScore ≥75 with at least 1 meta-analysis and 3+ RCTs

BScore ≥50 with at least 1 RCT or meta-analysis

CScore ≥25 — observational or animal evidence only

DScore <25 — very limited or preclinical data

Plain-English Snapshot

Glycine is currently categorized as a amino acid compound.

Evidence scoring has not been fully computed yet, so interpret this profile as preliminary.

Safety scoring is incomplete. Start conservatively and monitor carefully.

Core mechanism

Inhibitory glycine receptor agonist; NMDA co-agonist; collagen precursor; glutathione precursor via GCL; reduces core body temperature

Practical Context

Strongest current signals

No indexed study summaries yet.